A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 107
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CLA
Long Form : clarithromycin
No. Year Title Co-occurring Abbreviation
2019 Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. FZD, HP
2019 Continuous ozonation of urban wastewater: Removal of antibiotics, antibiotic-resistant Escherichia coli and antibiotic resistance genes and phytotoxicity. AMP, ARGs, AZM, DOC, ERY, HRTs, OFL, SMX, TC, TMP
2019 Data describing the effects of the Macrolide Antibiotic Clarithromycin on preclinical mouse models of Colorectal Cancer. CRC
2019 Effect of clarithromycin on the production of volatile fatty acids from waste activated sludge anaerobic fermentation. VFAs, WAS
2019 Genetic basis for metronidazole and clarithromycin resistance in Helicobacter pylori strains isolated from patients with gastroduodenal disorders. MDR, MTZ
2019 In silico and in vitro evaluation of tetrahydropyridine compounds as efflux inhibitors in Mycobacterium abscessus. AMI, CCCP, CIP, EtBr, MF, MICs, RFF, THP, VP
2019 Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants. EPI, NTM
2019 Tetrahydropyridine derivative as efflux inhibitor in Mycobacterium abscessus. AMI, CIP, M. abscessus, MIC, THP, VP
2019 Uptake and metabolism of clarithromycin and sulfadiazine in lettuce. SDZ
10  2018 Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. BVs, CIP, OC, SDM
11  2018 Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. AMX, CIP, HP, LVX, MTZ, TTC
12  2018 Hot spots of antibiotic tolerant and resistant bacterial subpopulations in natural freshwater biofilm communities due to inevitable urban drainage system overflows. CIP, CSO, Dox, NFB, OUR
13  2018 Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms. CF, P. aeruginosa, RH, TOB
14  2018 Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. AMO, LEV
15  2017 Activity of Amphotericin B and Anidulafungin Combined with Rifampicin, Clarithromycin, Ethylenediaminetetraacetic Acid, N-Acetylcysteine, and Farnesol against Candida tropicalis Biofilms. AmB, ANF, CBR, EDTA, FAR, NAC, PTFE, RIF
16  2017 Anti-Mycobacterium avium complex activity of clarithromycin, rifampin, rifabutin, and ethambutol in combination with adenosine 5'-triphosphate. ATP, EMB, MAC, RBT, RIF
17  2017 Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. AMO, H. pylori, LEV, MET, Tet
18  2017 Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals. AZI, ERY, RIF
19  2017 Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. FLQ, PUD
20  2017 In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. AMK, LZD, MOX, TGC
21  2017 Liquid Chromatographic-Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation. AMO, IS, LAN, PCR, PLSR
22  2017 Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. AMX, LEV, MICs, QRDR
23  2017 Relationship between Antibiotic Susceptibility and Genotype in Mycobacterium abscessus Clinical Isolates. SNP
24  2017 The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. ---
25  2016 A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn's disease associated with Mycobacterium avium subspecies paratuberculosis. CD, CLO, MAP, MIC, RIF
26  2016 Assessment of Sequential and Standard Triple Therapy in Treatment of Helicobacter pylori Infection in Children Dependent on Bacteria Sensitivity to Antibiotics. AMO, MET, PPI
27  2016 Clarithromycin ion pair in a liposomal membrane to improve its stability and reduce its irritation caused by intravenous administration. CHEMS, CIP-Lip, DL, EE
28  2016 Mycobacterium kansasii Subtype I Is Associated With Clarithromycin Resistance in China. AMK, LFX
29  2016 Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals. RIF
30  2016 RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn's disease associated with Mycobacterium paratuberculosis. CD, CLO, MAP, MIC, RIF
31  2015 Antimicrobial susceptibility of rapidly growing mycobacteria using the rapid colorimetric method. AMI, CIP, Dox, DST, LZD, MH, MHR, MXF, REMA, RGM, TMP-SMX
32  2015 Assessing antibiotic resistance of microorganisms in sanitary sewage. CIP, Dox, OUR
33  2015 Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice. RILI, TNF
34  2015 Group determination of 14-membered macrolide antibiotics and azithromycin using antibodies against common epitopes. AZI, BSA, CMO-CLA, ELISA, ERY, LOD, ROX
35  2015 High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. LFX, MICs, MTZ
36  2015 In vitro effect of bergamot (Citrus bergamia) juice against cagA-positive and-negative clinical isolates of Helicobacter pylori. AMX, BJ, MIC, MTZ
37  2015 In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. ALT, DAP, GM, TEC
38  2015 Microbiological assay for the analysis of certain macrolides in pharmaceutical dosage forms. ROX
39  2015 Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense. AMK, CPF, GAF, LVF, MXF, NTM
40  2015 Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. HP, LF
41  2015 Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching. HP, OME, TNZ
42  2014 Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm. DAP, EB, RIF, VAN
43  2014 First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic. AMO, BPMT, BS, HP, MET, PPI, Tet
44  2014 Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. BSA, CL
45  2014 Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. PVA
46  2014 Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. AH
47  2014 Optimization and evaluation of clarithromycin floating tablets using experimental mixture design. CDR 8th, OF
48  2014 Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? ---
49  2014 Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. AMO, CI, PPIs, RCTs, RR
50  2014 The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. pMDIs
51  2013 Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. AMX, MICs, MNZ, Tet
52  2013 Clarithromycin-loaded liposomes offering high drug loading and less irritation. CLA-Lip, SCS
53  2013 Dissolution rate enhancement of clarithromycin using ternary ground mixtures: nanocrystal formation. PVP, SLS
54  2013 Interplay of degradation, dissolution and stabilization of clarithromycin and its amorphous solid dispersions. ASD, CAAdP, GI, MIVM
55  2013 Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats. MTX
56  2012 Efficacy of clarithromycin on biofilm formation of methicillin-resistant Staphylococcus pseudintermedius. MRSP, SSIs
57  2012 Green synthesis of silver nanoparticles through reduction with Solanum xanthocarpum L. berry extract: characterization, antimicrobial and urease inhibitory activities against Helicobacter pylori. AMX, MNZ, SPR, SXE, TEM, Tet
58  2012 Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Chinese women with genital infectious diseases. Dox, JOS, MH, MIN, UU
59  2012 Rapid quantitative analysis of clarithromycin in rat plasma by UPLC-MS/MS after intravenous injection of the clarithromycin-loaded ultrafine PLGA nanoparticles. muSPE
60  2011 Characterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori. 23S-rRNA, MTZ
61  2011 LC-MS/MS method for the simultaneous determination of clarithromycin, rifampicin and their main metabolites in horse plasma, epithelial lining fluid and broncho-alveolar cells. BAC, DAc-RIF, ELF, RIF
62  2011 Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. H. pylori, ITT, MET, OME, OR, PP
63  2010 Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. BB, DAP, MOX, PB, PK/PD, RIF, VAN
64  2010 Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. MTZ
65  2010 Molecular characterization and susceptibility testing of Helicobacter pylori strains isolated in western Argentina. MTZ, PU, RAPD
66  2008 Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices. CFZ, VCM
67  2008 Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. AMO, LEV, MET, Tet
68  2008 Formulation and evaluation of gastroretentive dosage forms of Clarithromycin. H. pylori
69  2008 Interaction of the macrolide antimicrobial clarithromycin with dissolved humic acid. ESHA
70  2008 [Organizing pneumonia--clarithromycin treatment]. OP
71  2007 Development and validation of a spectrophotometric method for the determination of macrolide antibiotics by using 2,4-dinitrophenylhydrazine. AZ, ROX
72  2007 [Antimicrobial susceptibility of Ureaplasma urealyticum and ureaplasma parvum isolated from premature infants with respiratory disorders]. AZY, CIP, Dox, ERY, JOS, OFL, PRI, Tet, U.p, Uu
73  2007 [Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status]. AM, ITT, PP, RPZ
74  2007 [Prevalence of metronidazole, clarithromycin and tetracycline resistance in Helicobacter pylori isolated from Chilean patients]. MTZ, Tet
75  2006 In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. LEV, MET, Tet
76  2006 Liquid chromatographic-electrospray tandem mass spectrometric determination of clarithromycin in human plasma. MRM, MTBE, QC, ROX, RSD
77  2004 A comparative clarithromycin bioavailability study: determination of clarithromycin and 14-(R)-hydroxyclarithromycin under fasting and fed conditions. LLOQ
78  2004 Application of 3'-mismatched reverse primer PCR compared with real-time PCR and PCR-RFLP for the rapid detection of 23S rDNA mutations associated with clarithromycin resistance in Helicobacter pylori. 3M-PCR
79  2004 High level of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from pediatric patients in Poland (1997-2001). AMO, MET
80  2004 The activity of grepafloxacin in two murine models of Mycobacterium avium infection. EMB, GRE, i.n, MAC, RBT
81  2004 [Long-term therapeutic effect of triple therapy consisted of omeperazole, clarithromycin and amoxycillin in children with Helicobacter pylori infection and approach to re-treatment after failure of the treatment]. AMO, CBS, FUR, HP, MET
82  2002 Antibiotic susceptibility patterns of Helicobacter pylori strains isolated from northeastern Mexico. AMX, MTZ, Tet
83  2002 Comparison of telithromycin, a new ketolide, with erythromycin and clarithromycin for the treatment of Haemophilus influenzae pneumonia in suckling, middle aged and senescent mice. ERY
84  2002 Prophylactic clarithromycin to treat mycobacterium avium in HIV patients receiving zidovudine may significantly increase mortality by suppressing lymphopoiesis and hematopoiesis. HIV, LPS, MAC, ZDV
85  2001 Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. IDO, IL-12, ISS-ODN, TNF-alpha
86  2001 [Clarithromycin switch therapy in adult patients suffering from community-acquired lower respiratory tract infections (LRTIs) requiring hospitalisation]. LRTIs
87  2000 Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. MAC
88  2000 Dose-related stimulatory effect of clarithromycin on interdigestive gastroduodenal motility. ---
89  2000 Effect of clarithromycin on esophageal motility. LES
90  2000 Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up. AMO, DUs, HP, OME, PAN, PP, PPI
91  2000 In vitro comparative dynamics of modified-release clarithromycin and of azithromycin. AZI, MICs
92  2000 Virulence and drug susceptibility of Mycobacterium celatum. AZI, SO, ST
93  1999 A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. CAP, GFX
94  1999 Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige mice. AMI, CIP, CLO, EMB, RFB
95  1999 Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. AF
96  1998 Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. AECB, CIP
97  1997 Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. AIDS, AM, MAC, RBT
98  1997 Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. E test, MIC
99  1996 Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. AM, AZ, ELF
100  1996 [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. CBS, DU, FUR, HP, LAN